Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313976
Status:
WITHDRAWN
Last Update Posted:
2015-03-10
First Post:
2006-04-11
Brief Title:
Study to Compare Double-dose Betaferon to the Approved Dose for Patients With Early Secondary Progressive Multiple Sclerosis SPMS
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Scandinavian Randomized Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis
Status:
WITHDRAWN
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive Multiple Sclerosis SPMS
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer Schering Pharma AG Germany is the sponsor of the trial
Bayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 309560 | None | None | None |
| EudraCT 2005-001540-23 | None | None | None |